1-(Propyl)-(perfluorononane) | 1980076-60-5

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: 1-(Propyl)-(perfluorononane)
• 英文别名: 1,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9-nonadecafluorododecane
• CAS: 1980076-60-5
• 化学式: C₁₂H₇F₁₉
• 分子量: 512.15
• InChiKey: XHHKCWIIGJAQGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  19

文献信息

• Aminoalcohol lipidoids and uses thereof
  申请人：Massachusetts Institute of Technology

  公开号：US10844028B2

  公开（公告）日：2020-11-24

  Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

  本文介绍了通过胺与环氧化物封端化合物反应制备氨基醇脂质的方法。还提供了从市售起始原料制备氨基醇类脂质的方法。氨基醇脂质可由外消旋或立体化学纯环氧化物制备。氨基醇类脂质或其盐类最好具有生物降解性和生物相容性，可用于各种给药系统。考虑到这些氨基醇类脂化合物的氨基，它们特别适合用于多核苷酸的给药。现已制备出含有本发明类脂化合物和多核苷酸的复合物、胶束、脂质体或颗粒。本发明的类脂质还可用于制备给药微粒。由于本发明脂质具有缓冲周围环境 pH 值的能力，因此在递送易变药剂方面特别有用。
• Conjugated lipomers and uses thereof
  申请人：Massachusetts Institute of Technology

  公开号：US10933139B2

  公开（公告）日：2021-03-02

  The present invention provides inventive conjugated polyethyleneimine (PEI) polymers and conjugated aza-macrocycles (collectively referred to herein as “conjugated lipomers” or “lipomers”) containing one or more groups of the formula (iii): wherein R3 and R4 are as defined herein. Also provided are compositions comprising the inventive conjugated lipomers, and methods of preparation and use.

  本发明提供了创造性的共轭聚乙烯亚胺（PEI）聚合物和共轭杂大环（在此统称为 "共轭脂质体 "或 "脂质体"），它们含有一个或多个式(iii)基团： 其中 R3 和 R4 如本文所定义。此外，还提供了包含本发明共轭脂聚体的组合物，以及制备和使用方法。
• AMINO ACID-, PEPTIDE- AND POLYPEPTIDE-LIPIDS, ISOMERS, COMPOSITIONS, AND USES THEREOF
  申请人：Massachusetts Institute of Technology

  公开号：US20170165290A1

  公开（公告）日：2017-06-15

  Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R′, R 1 , R 2 , R 3 , R 4 , R 5 , R 8 , Z, W, Y, and Z are as defined herein.
• CONJUGATED LIPOMERS AND USES THEREOF
  申请人：Massachusetts Institute of Technology

  公开号：US20190167795A1

  公开（公告）日：2019-06-06

  The present invention provides inventive conjugated polyethyleneimine (PEI) polymers and conjugated aza-macrocycles (collectively referred to herein as “conjugated lipomers” or “lipomers”) containing one or more groups of the formula (iii): wherein R 3 and R 4 are as defined herein. Also provided are compositions comprising the inventive conjugated lipomers, and methods of preparation and use.
• LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA
  申请人：Translate Bio, Inc.

  公开号：US20220347099A1

  公开（公告）日：2022-11-03

  The present invention provides, among other things, methods of delivering mRNA in vivo, including administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo, wherein the liposome comprises a cationic lipid of formula I-c: or a pharmaceutically acceptable salt thereof.